Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The instigators hypothesize that IVIG, given in the acute phase following MI in patients at risk for developing HF, will improve cardiac performance, and by attenuating cardiac remodeling in this phase, such therapy will prevent the development of chronic HF resulting in long term beneficial effect also after the therapy has been stopped.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oslo University Hospital
• Collaborator: Helse Stavanger HF
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

• Age of 18-80 years

• Have a recent MI (<5days)

• Have ASAT >100 U/L or CKMB > 50 U/L.

• Have LVEF <40%.

• Are on optimal medical treatment and considered unsuitable for surgical intervention.

Exclusion Criteria:

• Evidence of unstable disease, concomitant ischemia or unstable angina during the hospitalization.

• Significant concomitant disease such as infections, pulmonary disease or connective tissue disease.

• Participating in other studies.

• Inability to participate.

• Diseases that require surgery.

• Planned revascularisation.

• Known hypersensitivity to IVIG.